Atherosclerosis Treatment in India & UAE

Atherosclerosis treatment in India from $1,500. Medical, interventional, and surgical management of arterial plaque at Apollo, Medanta, Fortis. Prevent heart attack and stroke. Expert cardiologists.

Estimated cost: $1,500 – $4,000 · Average stay: 2–5 days

Atherosclerosis — the buildup of cholesterol-rich plaques within the walls of arteries — is the underlying cause of the world's leading killer diseases: coronary artery disease, ischaemic stroke, and peripheral arterial disease. Globally, atherosclerotic cardiovascular disease accounts for over 18 million deaths annually. In India, the burden is particularly high: Indians develop atherosclerosis at a younger age, with more aggressive disease, and with a higher-risk genetic lipid profile (elevated Lp(a), low HDL, high small dense LDL) than Western populations. In the UAE, the combination of sedentary lifestyle, dietary excess, obesity, and diabetes has created one of the highest cardiovascular disease burdens in the Gulf region.

The good news is that atherosclerosis is both preventable and treatable. Modern cardiovascular medicine has an extraordinary toolkit for stabilizing plaques, preventing their rupture (which causes heart attacks and strokes), and even inducing some degree of plaque regression. High-intensity statin therapy (rosuvastatin, atorvastatin) reduces LDL cholesterol to target levels (below 1.8 mmol/L for very-high-risk patients) and has been proven to reduce cardiovascular events by 35–50% in landmark trials. Add-on therapies — PCSK9 inhibitors (evolocumab, alirocumab), ezetimibe, icosapent ethyl (fish oil), and newer agents like inclisiran — provide further LDL reduction for patients who cannot reach target on statins alone or who are statin-intolerant.

When atherosclerotic plaque significantly obstructs a coronary artery, interventional treatment — angioplasty and stenting, or bypass surgery — restores blood flow. When peripheral arterial disease obstructs limb blood flow, peripheral angioplasty, bypass surgery, or endarterectomy (plaque removal) restores perfusion. Carotid artery disease (plaque at the origin of the brain's blood supply) causing stroke risk is treated by carotid endarterectomy or carotid stenting.

India's cardiology and vascular medicine programs offer the full spectrum of atherosclerosis management — from comprehensive risk factor assessment and medical optimization through to complex coronary and peripheral revascularization — at world-class standards and significantly below Western costs.

What is Atherosclerosis and How Does it Cause Disease?

Atherosclerosis begins with endothelial dysfunction — damage to the smooth inner lining of arteries caused by high blood pressure, high LDL cholesterol, smoking, hyperglycemia, and inflammatory stimuli. Damaged endothelium becomes permeable to LDL cholesterol particles, which accumulate in the arterial wall and are oxidized. Oxidized LDL triggers an inflammatory response: monocytes enter the arterial wall and transform into macrophages that engulf the oxidized LDL, becoming "foam cells." The accumulation of foam cells, smooth muscle cells, fibrous tissue, and calcium forms the atherosclerotic plaque.

Stable plaques with thick fibrous caps cause gradual, predictable narrowing of the artery — producing exertional angina (chest pain with effort) when the coronary artery lumen narrows beyond 70%. Vulnerable plaques with thin fibrous caps and large lipid cores can rupture without warning, exposing the lipid core to the bloodstream, triggering an immediate blood clot (thrombus) that completely blocks the artery within seconds — causing an acute myocardial infarction (heart attack) if it involves a coronary artery, or ischaemic stroke if it involves a carotid or cerebral artery.

Risk factors that accelerate atherosclerosis include: dyslipidemia (high LDL, low HDL, high triglycerides, elevated Lp(a)); hypertension; diabetes and insulin resistance; smoking; chronic kidney disease; family history of premature cardiovascular disease; obesity; and sedentary lifestyle.

Who Needs Specialized Atherosclerosis Treatment?

All adults with established atherosclerotic cardiovascular disease (previous heart attack, stroke, peripheral artery disease, or revascularization) require intensive secondary prevention. High-risk individuals — those with multiple major risk factors, diabetes plus end-organ damage, severe dyslipidemia (familial hypercholesterolemia), or very high Lp(a) — benefit from specialist cardiology assessment to optimize medical therapy and ensure targets are met.

Patients who have not reached LDL targets on maximum tolerated statin and ezetimibe despite genuine adherence should be assessed for PCSK9 inhibitor therapy. Patients with symptomatic coronary, carotid, or peripheral arterial disease require imaging to determine whether revascularization will improve symptoms and reduce event risk.

Gaf Healthcare coordinates comprehensive atherosclerosis risk assessments at India's and the UAE's leading cardiac prevention and intervention centers, with results reviewed by preventive cardiologists, interventional cardiologists, and cardiac surgeons working collaboratively as a heart team.

Treatment Approaches for Atherosclerosis

Atherosclerosis treatment is stratified by cardiovascular risk category, symptom burden, and the degree of arterial obstruction.

Lifestyle Modification: The foundation of all atherosclerosis treatment. Smoking cessation, Mediterranean-style dietary pattern (high vegetables, fish, olive oil; low saturated fat and refined carbohydrates), daily moderate aerobic exercise (150 minutes/week), weight management, and alcohol reduction together reduce cardiovascular event risk by 30–50%. These measures also lower blood pressure, improve insulin sensitivity, reduce inflammation, and raise protective HDL cholesterol.

Medical Therapy: High-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) are the cornerstone — reducing LDL by 50–60% and cardiovascular events by 35–50% in high-risk patients. Add-on lipid-lowering therapy (ezetimibe, PCSK9 inhibitors) achieves very low LDL targets (under 1.4 mmol/L for very-high-risk patients with established disease) proven to further reduce events. Antiplatelet therapy (aspirin 75 mg, ticagrelor, clopidogrel) prevents clot formation at ruptured plaques. ACE inhibitors and ARBs treat hypertension, protect the kidneys in diabetics, and have direct anti-atherosclerotic effects. SGLT2 inhibitors and GLP-1 agonists for diabetic patients provide cardiovascular protection independent of glucose lowering.

Interventional/Surgical: Coronary angioplasty and stenting for obstructive coronary disease. Coronary bypass surgery for complex, multi-vessel coronary disease. Carotid endarterectomy or stenting for symptomatic carotid stenosis. Peripheral angioplasty and stenting, or bypass surgery, for limb ischaemia.

Procedure Steps

1. Comprehensive cardiovascular risk assessment: fasting lipid profile (LDL, HDL, TG, non-HDL), HbA1c, blood pressure, BMI, smoking status, family history, eGFR.
2. Advanced risk stratification: coronary calcium score (CT), ankle-brachial index (ABI), carotid intima-media thickness, Lp(a) measurement.
3. Risk category classification: SCORE2/HEART score calculation; very-high-risk vs. high-risk vs. moderate-risk stratification guides treatment intensity.
4. Lifestyle intervention: structured programme with dietitian, physiotherapist, and smoking cessation counsellor.
5. Medical optimization: statin titration to LDL target; add ezetimibe if target not met; consider PCSK9 inhibitor for very-high-risk patients with LDL still above target.
6. Imaging: stress testing (exercise ECG, nuclear myocardial perfusion scan, stress echo) to assess inducible ischaemia; coronary CT angiography for non-invasive coronary anatomy.
7. Coronary angiography: if imaging suggests obstructive coronary disease or symptoms are refractory — guides revascularization decision.
8. Revascularization if indicated: angioplasty/stenting or bypass surgery based on coronary anatomy, SYNTAX score, and heart team recommendation.
9. Secondary prevention: long-term follow-up; annual cardiovascular risk review; adherence monitoring; adjustment of therapies as evidence evolves.

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

United States — $3,000 – $15,000 (work-up and medical therapy) — Baseline

United Kingdom — $2,000 – $8,000 — ~45% savings vs. USA

India — $500 – $4,000 — Up to 87% savings vs. USA

UAE — $1,500 – $6,000 — ~65% savings vs. USA

Atherosclerosis assessment and management packages in India include the specialist cardiology consultation, advanced lipid panel (including Lp(a)), coronary calcium score (non-contrast CT), carotid duplex ultrasound, echocardiogram, and a personalized risk reduction plan. Medical therapy (statins, PCSK9 inhibitors) costs significantly less in India than in Western countries. Interventional procedures (angioplasty, bypass) are priced separately as all-inclusive packages.

Recovery & Follow-up

Medical management of atherosclerosis is an ongoing lifelong process — there is no "recovery" per se. Patients begin medical therapy, make lifestyle changes, and return for regular monitoring. The goal is LDL achievement, blood pressure control, HbA1c optimization, smoking cessation, and weight management — all measured at follow-up visits every 3–6 months initially, then annually when stable.

For patients who require revascularization, recovery follows the timelines specific to the procedure (angioplasty, bypass surgery, peripheral procedure). Cardiac rehabilitation after any coronary revascularization is strongly recommended and reduces subsequent cardiovascular events by 20–25%.

Recovery Tips

• Take statins at night (when cholesterol synthesis is highest) consistently — do not miss doses.
• Track your LDL at every blood test — know your number and your target (under 1.8 mmol/L for established disease).
• Exercise 150 minutes of moderate aerobic activity weekly — the single most powerful lifestyle intervention for atherosclerosis.
• Quit smoking completely — even passive smoking accelerates plaque progression.
• Manage blood pressure to below 130/80 mmHg — consider home blood pressure monitoring.
• Attend annual cardiovascular risk review — medication adjustments are frequently needed as evidence evolves.
• Consider cardiac rehabilitation if you have had a heart attack, angioplasty, or bypass surgery.

Risks & Complications

Atherosclerosis itself, if inadequately treated, carries the highest risk of any chronic condition — heart attack, stroke, and premature cardiovascular death. Treatment risks relate to specific interventions: statins occasionally cause myalgia (muscle pain, 5–10%) or, rarely, elevated liver enzymes (under 1%); PCSK9 inhibitors are very well tolerated. Interventional procedures carry their specific risks (discussed under angioplasty and bypass surgery entries).

Why GAF Healthcare

Gaf Healthcare coordinates comprehensive cardiovascular prevention assessments and revascularization planning in India and the UAE. Our cardiac team identifies the right combination of medical, interventional, and surgical management for each patient's specific atherosclerotic burden, risk factor profile, and coronary anatomy. We ensure you leave with a personalized, evidence-based risk reduction plan that your home doctors can continue.

Frequently Asked Questions

Can atherosclerosis be reversed?

Atherosclerosis cannot be fully reversed, but intensive medical therapy (high-intensity statins, PCSK9 inhibitors, lifestyle change) can slow progression, stabilize vulnerable plaques, and induce modest plaque regression on imaging. The cardiovascular event rate is dramatically reduced even when plaque burden decreases only modestly, because the plaques that remain are stabilized and less prone to rupture.

What LDL target do I need?

For patients with established atherosclerotic cardiovascular disease (previous heart attack, stroke, coronary stent, peripheral arterial disease), current ESC/ACC guidelines recommend LDL below 1.4 mmol/L (55 mg/dL). For primary prevention in high-risk individuals, below 1.8 mmol/L (70 mg/dL) is recommended. Achieving these targets requires statin, ezetimibe, and often a PCSK9 inhibitor.

How do I know if I have atherosclerosis before it causes symptoms?

A coronary calcium score (non-contrast CT) is the most powerful way to detect silent coronary atherosclerosis. A calcium score above 100 indicates significant plaque burden and identifies individuals at high cardiovascular risk who benefit from intensive preventive therapy. Other tests — carotid intima-media thickness, ankle-brachial index, and Lp(a) — complete the risk picture.